TO THE EDITOR:
Throughout the last decade, thousands of refugees arrived on a daily basis at the Mediterranean coast of Southern European countries. Because this influx is not expected to slow down, the development of national and European strategies is required to ensure appropriate and accessible health care to these vulnerable populations.1,2 The vast majority of these migrants come from areas in which sickle cell disease (SCD) and other hemoglobinopathies are highly prevalent. Limited data are available on the burden of these disorders in populations of refugees. Here, we present 2 pieces of evidence supporting the need for specific strategies for the early identification of SCD in refugees. First, we carried out a retrospective study of data collected from 2014 to 2017 across 13 Italian reference centers for SCD and hemoglobinopathies. The primary outcome of this study was to identify events associated with the new diagnosis of SCD in refugees; the secondary outcome was to evaluate the impact of hemoglobinopathies in refugees coming from endemic areas. The descriptive analysis of variables was performed with counts, percentages, mean and standard deviation (SD), or median and interquartile range (IQR; 25th-75th percentile). Then, we discuss the results of a pilot study that screened all refugees seen in a single second-level refugee center during October 2017, using 1 of the new rapid point-of-care screening devices (Sickle SCAN; BioMedomics). The aim was to fast-track the care of individuals with SCD and the collection of relevant demographic data.3-5 The results were validated by high-performance liquid chromatography, the standard gold-standard screening method.3-5
Based on data from the Italian Ministry of the Interior, a total of 624 688 refugees landed on the Italian coast between 2014 and 2017 (Figure 1A).6 Refugees from Syria represented only 4% to 25% of these each year (Figure 1A-B), whereas 21% to 53% came from sub-Saharan African countries (21% in 2014, 31% in 2015, 53% in 2016, and 46% in 2017). Refugees generally disembark at known hotspots on the coast of Southern Italy. They are then relocated in second-level reception centers throughout the country, before being screened for communicable diseases and undergoing the vaccination program recommended by the World Health Organization within 2 weeks of their arrival. Screening for noncommunicable disorders, such as SCD, is not conducted. SCD is a common red cell disorder identified as a global health priority by the African Union and the World Health Organization.7,8 Life-threatening complications of SCD include acute vaso-occlusive painful events, acute chest syndrome, and splenic sequestration, which require early identification and intensive clinical management. In addition, dehydration, psychological stress, and exposure to high/low temperatures can trigger vaso-occlusive events in patients with SCD. Refugees represent marginalized and vulnerable people who are exposed to extreme conditions during their travels, mostly through Africa, to the coast of Southern European countries. The delay in the identification of SCD may lead to severe acute organ complications and fatal outcomes.9,10 To help manage acute health problems related to SCD that might dominate the first phase of transition of refugees, we have developed an algorithm for the management of acute events in the emergency department (ED) and we promoted specific knowledge of SCD, with training sessions and seminars dedicated to physicians in EDs, pediatricians, hematologists, and internal medicine physicians.10
Our retrospective study shows that SCD is relatively common in refugees visiting EDs for acute sickle cell–related events. Over the 4 years studied, we identified 70 patients with hemoglobinopathies: 50% were adults (86% male; 14% female; median age, 21 years; IQR, 18.5-19 years), and 50% were children (80% male; 20% female; median age, 10 years; IQR, 1-16 years). The number of refugees with SCD arriving in Italy between 2014 and 2017 revealed a peak in 2016 (48%) corresponding to the arrival of a large number of refugees from sub-Saharan Africa (41%) (Figure 1). The overall genotypic distribution was as follow: SS (n = 49), SC (n = 9), Sβ-thalassemia (n = 3), CC (n = 2), AS (n = 1), and transfusion-dependent β-thalassemia (TDT; n = 6). The analysis of genotypes combined with patient origin revealed that 61.4% of the SS individuals identified were from sub-Saharan Africa (Figure 1C). SC patients were mainly from West African countries, whereas TDT patients were from Syria (7.1%) and Bangladesh (1.4%) (Figure 1C). As shown in Figure 2A, acute events were primarily responsible for the identification of SCD in refugees. The main reasons for access to ED of previously undiagnosed SCD were qualitatively similar to those seen in the native Italian SCD population11 or other SCD groups,12,13 with the exception of anemia, which was the second main cause of visits to the ED in our study population. Although we did not have access to historical patient hematologic data, we cannot exclude the possible contribution of malnutrition to anemia in refugees with SCD. Among the individuals with SCD for whom hemoglobin (Hb) data were recorded (n = 46), 15% had Hb levels <8 g/dL, and 85% had Hb levels ≥8 g/dL. This is consistent with a recent report of data from German refugee centers, in which anemia was recognized in 22.5% of the refugees.14 A total of 82.9% of patients was diagnosed with SCD within the first 11 months after their arrival in Italy, and 14.3% were diagnosed during the second year. The main identifying signs of SCD in our group of patients are summarized in Figure 2A; in a small group, SCD was also identified outside acute events. Among these, 2.9% were identified through early pregnancy counseling or through the management of pregnancy complications related to severe clinical manifestations due to SCD (venous cerebral thrombosis, 1.4%) or obstetrical complications (spontaneous abortion, 1.4%).15 Collectively, our results indicate the need for screening for SCD in refugees at their arrival to prevent severe acute and life-threatening clinical manifestations. This is also supported by a document from the Division of Global Migration and Quarantine of the US Department of Health and Human Services,16 as well as by the introduction of SCD screening by Canadian health authorities because of the increasing prevalence of SCD related to migration fluxes in North America.17 Indeed, our prospective study screening asymptomatic refugees in a second-level refugee center identified 3% SCD patients and 20% AS individuals over 400 screened individuals. The analysis of genotypes, combined with data on patients’ origins, revealed that 2.6% of SCD patients were from sub-Saharan Africa. HbS carriers were from Nigeria (11.5%), Guinea (2.6%), Ivory Coast (2.1%), and Senegal (1.6%), whereas 0.5% each were from Burkina Faso, Gambia, Ghana, and Guinea Bissau; HbC carriers were from Ivory Coast (1%), Ghana (1%), Guinea (1%), Mali (0.5%) and Nigeria (0.5%); HbD carriers were from Nigeria (0.5%); and the β-thalassemia carriers were from Gambia (0.5%) and Guinea (0.5%). A total of 71.4% of the individuals screened did not have any hemoglobinopathy. None of the newly identified SCD patients were aware of their condition.
Because SCD and β-thalassemia are endemic to several parts of Italy, a national network of reference centers has been established in the last 5 decades for the clinical management of these patients, ensuring preconception counseling and prenatal diagnosis.18 In addition, this network allowed the identification of the ongoing epidemiological change across the country.11,19-21 This makes the Italian experience unique compared with other European countries with a lower incidence of SCD. In our study, refugees with SCD were all redirected to the comprehensive SCD centers of the area. 60% of them were admitted or referred to an SCD center within 11 months after their first visit to an ED, and 32.9% within the second year. Patients with SCD were treated with hydroxyurea and followed-up by the comprehensive SCD centers of the area. A multidisciplinary working group on health care in refugees is now analyzing the possibility of introducing routine screening of SCD as a noncommunicable disorder in refugees.
In conclusion, our data support the recommendation that refugees coming from areas endemic for SCD should be screened for the disease. To appropriately address this problem and to face the dynamic changes in the distribution and prevalence of SCD in European countries, we propose (1) the development of flow charts facilitating the early and systematic identification of SCD in refugees at their arrival or in second-level refugee camps; (2) to educate health professionals, such as ED physicians, pediatricians, internal medicine doctors, and hematologists, about the early identification and treatment of acute vaso-occlusive events; (3) to rapidly refer refugees with SCD or symptomatic HbS-carrier refugees to the comprehensive SCD reference center for treatment and follow-up; and (4) to rapidly start disease-modifying treatment, such as hydroxyurea. These actions will allow for the earlier identification of patients with SCD, preventing severe complications and decreasing the overall health care costs associated with this population.
BioMedomics provided Sickle SCAN devices as a restricted donation.
This work was supported by Fondo Universitario di Ricerca-Università degli Studi di Verona (L.D.F.) and by Società Italiana Talassemie ed Emoglobinopatie (B.G.).
Contribution: L.D.F., F.B.P., and G.L.F. designed the study, analyzed the data, and wrote the manuscript; B.G. analyzed the data and wrote the manuscript; and C.L., F.B., M.C., G.G., R.L., V.P., M.C.P., P.R., R.R., G. Ruffo, G. Russo, V.S., C.P., M.R., and F.M. were involved in clinical identification of SCD and data collection.
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Correspondence: Lucia De Franceschi, Department of Medicine, University of Verona and AOUI Verona, Policlinico GB Rossi, P.Le L. Scuro, 10, Verona, Italy; e-mail: email@example.com.